News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
329 Results
Type
Article (7)
Company Profile (1)
Press Release (321)
Section
Business (66)
Deals (10)
Drug Development (105)
FDA (7)
Job Trends (3)
News (198)
Policy (26)
Tag
Alliances (16)
Antibody-drug conjugate (ADC) (1)
Approvals (7)
Best Places to Work (1)
Biotechnology (1)
Cancer (4)
Cell therapy (1)
Clinical research (93)
Collaboration (1)
Data (2)
Earnings (25)
Events (35)
FDA (8)
Funding (1)
GLP-1 (2)
IPO (5)
Job creations (2)
Legal (1)
Lung cancer (2)
Manufacturing (1)
Mergers & acquisitions (6)
NextGen: Class of 2026 (2)
People (24)
Phase 1 (9)
Phase 2 (49)
Phase 3 (37)
Pipeline (1)
Postmarket research (3)
Preclinical (9)
Radiopharmaceuticals (6)
Regulatory (27)
Series B (1)
Startups (5)
Vaccines (3)
Date
Last 365 days (14)
2026 (1)
2025 (15)
2024 (15)
2023 (8)
2022 (3)
2021 (5)
2020 (9)
2019 (7)
2018 (7)
2017 (22)
2016 (18)
2015 (24)
2014 (24)
2013 (38)
2012 (35)
2011 (31)
2010 (27)
Location
Asia (11)
Australia (3)
California (12)
Canada (2)
China (1)
Europe (23)
Massachusetts (1)
Nevada (1)
Northern California (8)
Pennsylvania (1)
South America (1)
Southern California (3)
United States (14)
329 Results for "abdera therapeutics.rss".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Abdera Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13
December 19, 2025
·
1 min read
Press Releases
Abdera Therapeutics Appoints Rachael Brake, Ph.D., as Chief Scientific Officer
July 8, 2025
·
5 min read
Press Releases
Abdera Therapeutics Presents Initial Phase 1 Clinical Data on ABD-147, a Next-generation DLL3-targeting Radiopharmaceutical Therapy, at IASLC 2025 World Conference on Lung Cancer
September 9, 2025
·
6 min read
Press Releases
Abdera Therapeutics to Present Early Pharmacokinetics, Dosimetry and Safety Data from Ongoing Phase 1 Trial of ABD-147 at the IASLC 2025 World Conference on Lung Cancer and Participate in Upcoming Investor Conferences
August 27, 2025
·
3 min read
FDA
Abdera Therapeutics Announces FDA Clearance of IND Application for ABD-147
Abdera Therapeutics Inc. today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for ABD-147.
May 23, 2024
·
5 min read
Press Releases
Abdera Therapeutics to Present Key Updates on its Radiopharmaceutical Development Pipeline at the 2025 American Association for Cancer Research (AACR) Annual Meeting
April 23, 2025
·
5 min read
Business
Abdera Therapeutics Expands Management Team and Board of Directors
Abdera Therapeutics Inc. today announced the appointments of Philippe Bishop, M.D., as chief medical officer and Eric Dobmeier as a member of the company’s board of directors.
January 30, 2024
·
4 min read
Press Releases
Abdera Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
January 9, 2025
·
3 min read
FDA
Abdera Therapeutics Announces FDA Fast Track Designation for ABD-147, a Next-Generation Precision Radiopharmaceutical Therapy, for the Treatment of Patients with Extensive-stage Small Cell Lung Cancer
Abdera Therapeutics Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ABD-147 for the treatment of patients with extensive stage small cell lung cancer (ES-SCLC) who have progressed on or after platinum-based chemotherapy.
June 27, 2024
·
4 min read
Business
Abdera Debuts with $142M to Develop Precision Radiopharmaceuticals
Abdera Therapeutics will use the money to fund its ROVEr platform and advance its lead asset ABD-147 for small-cell lung cancer.
April 20, 2023
·
2 min read
·
Tristan Manalac
1 of 33
Next
